ETV4 and pancreatic neoplasm: Numerous studies have shown that high expression of ETV4 in prostate cancer (51), breast cancer (52), colorectal cancer (53), pancreatic cancer (54), and cholangiocarcinoma (55) often correlates with poor prognosis.